The global anti-inflammatory biologics market size is expected to reach USD 149.80 billion by 2027, exhibiting a CAGR of 11.0% during the forecast period. The indication of an inflammatory surplus in patients with COVID-19 along with plentiful neutrophils and macrophages will revivify growth prospects for the anti-inflammatory biologics market share during the forecast period. The ongoing trials for anti-tumor necrosis factor (TNF) antibodies in severe cases of autoimmune inflammatory disease such as rheumatoid arthritis, inflammatory bowel disease, or ankylosing spondylitis will aid the speedy expansion of the market during the forecast period, mentioned by Fortune Business Insights.
Anti-Inflammatory Biologics Market Size, Share & Industry Analysis, By Drug Class (Anti-Tumor Necrosis Factor (TNF), Interleukin Antagonists, Janus Kinase (JAK) Inhibitors, Others), By Application (Rheumatoid Arthritis, Psoriasis, and Others), By Route of Administration (Oral and Injection (Subcutaneous and Intravenous)), By Distribution Channel (Hospital Pharmacy Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027” the market size stood at USD 64.84 billion in 2019.
Ongoing Trails for Anti-Tumour Necrosis Factor Therapy to Benefit COVID-19 Patients
The increasing R&D investments by major players for the development of biologics will promote market growth in the forthcoming years. The rising number of deaths from coronavirus (COVID-19) has steered pharmaceutical companies to invest in potential drug candidates. The growing prominence of TNF in acute inflammatory reactions will have a positive impact on the market. Similarly, the ongoing research for anti-TNF therapy in patients with COVID-19 for counteraction and prevention will tremendously influence the market in the forthcoming years.
Moreover, the advent of novel biological therapies and monoclonal antibodies by biopharma giants will facilitatethe healthy growth of the marketduring the forecast period. For instance, in December 2019, UCB S.A, a multinational biopharmaceutical company announced positive results from the phase 3 clinical study of Bimekizumab for the treatment of psoriasis. Also, the escalation in applications of existing biologics for rare anti-inflammatory diseases such as lupus, diffuse systemic sclerosis, and others will enhance business scenarios of the market
Increasing Cases of Inflammatory Diseases to Boost Growth in North America
The market in North America stood at USD 28.63 billion in 2019. The growth of the region is attributed to rising government support for the introduction of biosimilars in the region. The potential pipeline candidates along with demand for anti-TNF drugs will aid healthy growth of the market in the region. The increasing prevalence of rheumatoid arthritis will spur demand for the market in North America. The approval of novel drugs will favor growth in Europe in the foreseeable future.
For instance, in October 2018, Mylan announced the commercial launch of Hulio, a biosimilar of adalimumab. Asia Pacific is predicted to grow rapidly during the forecast period owing to the growing geriatric population. The increasing preference for biologics for inflammatory diseases will boost the market in Asia Pacific. The Middle East and Africa is likely to rise steadily in the forthcoming years owing to the improving healthcare infrastructure and rising disposable income.